Iktos’s AI-driven Drug Discovery Platform
Iktos has developed an artificial intelligence-driven drug discovery platform which allows drug designers to rapidly iterate over millions of drug candidates and identify the most promising compounds. This platform is used by drug researchers at major pharmaceutical companies and leading academic institutions across the world.
The platform is built on a deep learning approach which uses generative models to automatically generate novel molecules from scratch. The technology has been proven to discover novel molecules with the desired properties for a variety of therapeutic applications.
Iktos Robotics: Automated End-to-End Drug Discovery
The new Series A financing will enable Iktos to expand its existing AI technology platform and launch a pioneering end-to-end drug discovery platform. This platform, Iktos Robotics, combines artificial intelligence and automated chemical synthesis to accelerate the timelines of drug discovery. Iktos Robotics will allow scientists to quickly design and synthesize novel molecules and obtain the desired compounds.
The platform will also feature a suite of analytical tools which will provide users with detailed information about the molecules they are working on. This will enable researchers to identify the most promising drug candidates with greater accuracy and speed.
- Iktos Robotics will provide a comprehensive solution, reducing the time and cost of drug discovery.
- Iktos Robotics will enable drug designers to rapidly iterate over millions of drug candidates and identify the most promising compounds.
- The platform will feature a suite of analytical tools which will provide users with detailed information about the molecules they are working on.
The new Series A funding will enable Iktos to further develop its AI and drug discovery capabilities and launch Iktos Robotics; a unique, end-to-end, drug discovery platform. This new platform will provide drug designers with an automated and efficient solution for drug discovery, ultimately helping to speed up the development of new treatments for a wide range of diseases.
This new platform will also allow researchers to harness the power of AI and automate their drug discovery processes, enabling them to develop new and improved treatments faster than ever before.
The successful completion of this round demonstrates the continued trust and commitment of investors in Iktos’s vision and mission to revolutionize the drug discovery process.
Iktos is building a future in which drug discovery is faster, more efficient and more successful, allowing pharmaceutical companies to develop treatments for a wide range of diseases with greater speed and accuracy.
This new round of funding will allow the company to continue to grow and develop its AI-driven drug discovery platform, enabling it to provide the best possible solutions for the pharmaceutical industry.
The Iktos team is committed to building a better future for drug discovery and is excited to continue to push the boundaries of AI-driven drug discovery with the support of its investors.
With this new series A funding, Iktos is well positioned to become the leader in AI-driven drug discovery, creating an environment in which drug discovery is faster, more efficient and more successful.
„We are extremely impressed by the Iktos team’s achievements in such a short period of time, as well as by the breadth of their collaborations in the industry. Iktos is a pioneer in the application of AI to drug discovery and development and we are thrilled to be part of their journey in this space.”
AI-Powered Drug Discovery
The Iktos AI-powered drug discovery platform, which combines generative deep learning models with high-performance computing, tackles a significant challenge in drug discovery and design. This platform enables the generation of a vast number of high-quality, diverse molecules and their subsequent fast optimization. It is built to integrate seamlessly with other existing drug discovery tools and platforms.
Benefits of AI-Powered Drug Discovery
- Speeding up the drug discovery process
- Increasing the probability of success of drug candidates reaching clinical development
- Generating vast number of high-quality, diverse molecules
- Fast optimization of molecules
- Integrating seamlessly with other existing drug discovery tools and platforms
Iktos’ AI-powered drug discovery platform provides a unique and ground-breaking approach to drug discovery and design. It is already validated by Iktos through more than 50 academic and industrial collaborations, with multiple pharmaceutical and biotech companies.
By drastically accelerating the process of drug development, Iktos can potentially revolutionize the way drugs are discovered and developed, with the ultimate goal of improving the health of people around the world. The potential of this revolutionary approach is only beginning to be explored, and the future of AI-powered drug discovery looks very promising.
Iktos is a leading Artificial Intelligence (AI) company in Drug Discovery and Development (AIDD). With its mature AI technologies, Iktos is advancing the development of drugs to clinical entry, shortening drug discovery cycle times and reducing costs. Iktos’ AI technologies are applied in various therapeutic areas, including oncology, metabolic disorders, and rare diseases.
Debiopharm Innovation Fund and M Ventures
Debiopharm Innovation Fund is a venture capital fund investing in early- and growth-stage companies. They focus on investments in healthcare, primarily in the areas of diagnostics, medical devices, digital health and therapeutics. M Ventures is the corporate venture capital arm of Merck, a global leader in healthcare, life science and performance materials.
Omnes Capital
Omnes Capital is a leading private equity firm in Europe. With its strong network of investors, Omnes Capital has been providing equity and debt financing to young and innovative companies. Omnes Capital is committed to helping companies speed up the process of commercialization of their products and services.
Collaboration with the Three Investors
Iktos has recently announced its collaboration with Debiopharm Innovation Fund, M Ventures and Omnes Capital, three of the leading investors in the healthcare and life sciences industry. Through this collaboration, Iktos will be able to access the resources and expertise of the three investors to accelerate its development of end-to-end AIDD capabilities.
The collaboration between Iktos and the three investors provides a great opportunity to both parties. Iktos will benefit from the resources and expertise of the three investors while the investors will gain access to Iktos’ cutting-edge AI technologies in drug discovery and development. This collaboration will accelerate the development of drugs to clinical entry, shortening drug discovery cycle times and reducing costs.
The potential of this collaboration is immense. With the help of these investors, Iktos will be able to bring forth meaningful advancements in building a fully integrated drug discovery platform and accelerating processes to clinical entry. This will help the pharma industry to gain a competitive edge and make full use of AI/ML in R&D.
The collaboration between Iktos and the three investors is a great example of how AI can be used to revolutionize the healthcare industry. With the help of AI, the pharma industry can reduce drug discovery cycle times, accelerate processes to clinical entry, and reduce costs. AI can also help to improve the quality and accuracy of drug development, bringing forth meaningful advancements in the healthcare industry.
To summarize, the collaboration between Iktos and the three investors is an important step in the development of AI technologies in drug discovery and development. This collaboration will enable Iktos to access the resources and expertise of the three investors and make full use of AI/ML in R&D, thus revolutionizing the healthcare industry.
Moreover, this collaboration will enable Iktos to capitalize on the opportunities that AI brings to the industry and bring forth meaningful advancements in drug discovery and development. With the help of this collaboration, the pharma industry will gain a competitive edge and be able to reduce drug discovery cycle times and accelerate processes to clinical entry at a lower cost.
In conclusion, this collaboration between Iktos and the three investors will be beneficial for both parties and revolutionize the healthcare industry. It will open up new opportunities for the pharma industry to make use of AI/ML in R&D and reduce drug discovery cycle times, accelerate processes to clinical entry, and reduce costs. This will create a win-win situation for both parties and benefit the healthcare industry as a whole.
M Ventures is the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and is focused on investing in and partnering with start-ups and entrepreneurs in the health and life sciences space.
Iktos, a French Start-up
Iktos is a French start-up specializing in the development of artificial intelligence (AI) solutions applied to chemical research. The company is focused on medicinal chemistry and new drug design, offering a proprietary and innovative solution based on generative deep learning models. This solution allows to design optimized molecules in silico, from existing data, to meet all the success criteria of a small molecule discovery project.
The use of the Iktos technology platform enables major productivity gains in upstream pharmaceutical R&D. The technology is available both as professional services and as a SaaS software platform, called Makya™. Additionally, Iktos develops Spaya™, a synthesis planning software based on Iktos’ proprietary AI technology for retrosynthesis.
Iktos and Merck KGaA, Darmstadt, Germany
Iktos has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies such as Chiesi Group, Galapagos, Janssen, Merck, Teijin, Ono Pharmaceuticals, Pfizer, Servier, UCB… Merck KGaA, Darmstadt, Germany is one of the first companies to invest in Iktos. Through its corporate venture capital arm, M Ventures, Merck KGaA, Darmstadt, Germany is focused on investing in and partnering with start-ups and entrepreneurs in the health and life sciences space.
- Iktos is a French start-up specializing in the development of AI solutions applied to chemical research.
- The company offers a proprietary and innovative solution based on generative deep learning models.
- Iktos’ technology platform enables major productivity gains in upstream pharmaceutical R&D.
- The technology is available both as professional services and as a SaaS software platform.
- Iktos has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies.
- M Ventures is the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and is focused on investing in and partnering with start-ups and entrepreneurs in the health and life sciences space.
Iktos is a leading example of the power of Artificial Intelligence in the pharmaceutical industry, with the potential to accelerate the process of drug development and improve the quality of life of many people. The collaboration with Merck KGaA, Darmstadt, Germany is a testament to the impact that Iktos is making in the pharmaceutical industry.
Omnes Capital is a leading European private equity firm dedicated to mid-market companies. With €2.7 billion in assets under management, Omnes Capital provides companies with the resources they need to finance their growth and drive their development over the long-term. Omnes Capital has teams in Paris, Lyon, Nantes, Lille, London, Madrid, Milan and Luxembourg.
Korzyści dla inwestorów
- Możliwość inwestowania w globalne pomysły zmieniające świat
- Aktywne wsparcie w zarządzaniu portfelem inwestycji
- Systematyczna identyfikacja i finansowanie nowatorskich rozwiązań
- Inwestycje w obszarach mających wpływ na odporność i trwałość biznesu
- Finansowanie i wsparcie dla firm chcących skutecznie przekształcać farmację
- Inwestycje w liderów rund inwestycyjnych
- Środki na długoterminowy rozwój spółek
Inwestorzy mogą czerpać korzyści z globalnego partnerstwa Merck, Debiopharm oraz Omnes Capital. Wszyscy inwestorzy mają możliwość współpracy z przedsiębiorcami na całym świecie, aby wspólnie tworzyć przyszłość opartą na innowacjach.
Omnes Capital
Omnes Capital jest ważnym graczem na rynku prywatnych funduszy inwestycyjnych i infrastruktury. Mając ponad 5 miliardów euro aktywów pod zarządzaniem, Omnes dostarcza firmom kapitału potrzebnego do rozwoju dzięki swoim 3 podstawowym biznesom: venture capital, expansion capital & LBO oraz infrastrukturze. Omnes jest w 100% własnością jej pracowników. Firma jest zaangażowana w sprawy ESG i stworzyła Fundację Omnes na rzecz dzieci i młodzieży. Jest sygnatariuszem Zasad Odpowiedzialnego Inwestowania (PRI) ONZ.
Omnes ma szeroką gamę produktów i usług dla inwestorów:
- Venture Capital – wsparcie w rozwoju start-upów,
- Rozszerzenie Kapitału & LBO – wsparcie w restrukturyzacji i przejęciach,
- Infrastruktura – inwestycje w infrastrukturę,
- Private Debt – pożyczki dla firm,
- Real Estate – inwestycje w nieruchomości.
Dzięki swojemu długoterminowemu zaangażowaniu, Omnes Capital jest idealnym partnerem dla firm, które chcą rozwijać swoje działania w długim okresie czasu. Co więcej, wszystkie produkty i usługi są świadczone w zgodzie z zasadami ESG.
Omnes Capital zapewnia inwestorom szeroki zakres produktów i usług, aby pomóc im osiągnąć sukces. Firma stale pracuje nad wprowadzaniem nowych produktów i usług, aby odpowiedzieć na potrzeby klientów. Fakt, że firmę w 100% własnością jej pracowników, świadczy o jej silnym zaangażowaniu w tworzenie produktów i usług na najwyższym poziomie. Dzięki temu, Omnes Capital jest w stanie dostarczyć swoim inwestorom wysokiej jakości usługi, które pomogą im w osiąganiu sukcesów.
Łącząc zaawansowaną wiedzę z zakresu inwestycji z zaangażowaniem w sprawy ESG, Omnes Capital jest idealnym partnerem dla firm, które chcą osiągnąć swoje cele biznesowe i jednocześnie przyczynić się do dobra publicznego.
Pochodzenie informacji: pap-mediaroom.pl
